TBIO dividend history
Telesis Bio Inc. (TBIO) dividend declarations and ex-dividend dates - real-time wire coverage of every payout disclosure.
Recent dividend items
- Telesis Bio Reports First Quarter 2024 Financial ResultsSAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the first quarter of 2024. In discussing results, recently appointed President and CEO Eric Esser said, "I am pleased with our performance as we execute against our strategy to focus on Gibson SOLA and BioXp mRNA solutions. Our BioXp mRNA offerings continue to gain traction and are delivering real improvements in speed and simplicity to our customers in their discovery workflows. I'm also excited abo
- Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial ResultsSAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the fourth quarter and year ended December 31, 2023. Results highlight strong BioXp® kit sales, expanding gross margin and reduced operating expense. In discussing the results, Todd R. Nelson Ph.D., Founder and CEO of Telesis Bio said, "I'm pleased with our operating execution in a challenging macro environment during 2023. Our company experienced record BioXp kits sales and expanding gross margin aga
- Telesis Bio Reports Third Quarter 2023 Financial ResultsSAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the third quarter of 2023. "This quarter, we continued to drive adoption of our instruments and kits, make progress against important collaborations, advance our mRNA strategy, and strengthen both our Board of Directors and Management Team," said Todd R. Nelson, PhD, CEO, and founder of Telesis Bio. Highlights Strengthened board of directors and management team: Appointed Greg Herrema, Senior Advisor to Novalis LifeSciences to the Telesis Bio board of directors in October 2023. Mr. Herrema's distinguished car